Latest news with #Biopeak
Mint
4 days ago
- Health
- Mint
India has the potential to be a global lab for scalable longevity solutions: Accel's Prashanth Prakash
Bengaluru-based wellness startup Biopeak had raised $3.5 million recently in a funding round led by Prashanth Prakash, founding partner of Accel Partners, that also saw participation from Manipal Group's Ranjan Pai through his investment vehicle Claypond Capital and Zerodha's Nikhil Kamath and Nithin Kamath. In this exclusive interview, Prakash talks about longevity as a concept and its importance in future. Excerpts: Hello Prashanth, what was the thought process behind this investment decision? The timing of this investment is deeply intentional. We are at a unique intersection in human health where diagnostics, artificial intelligence, and longevity science are converging with extraordinary speed. Biopeak is building an integrated, precision health system grounded in global science but tailored to the unique biological, environmental, and lifestyle factors of the Indian population. This is not just a business bet—it's a belief that India will lead the world in next-generation healthcare. The thought process was simple: medicine is shifting from reactive to predictive and preventive, and Biopeak is among the few platforms architecting that future in a scalable, scientifically grounded way. It will enable us to plot with unprecedented detail personalised health trajectories for a specific individual using multi-dimensional data collection, integration, and prediction. The focus on deeply personalised healthcare is going to be huge in the future. Right? The transition from universal averages to personalised insights will represent a revolution in how we detect, predict, prevent adverse events and build resilience reserves. This new model of Biology and AI-led medicine is an exciting paradigm for the future of healthcare in our country that investors are excited to back. What's your definition of longevity? Longevity, for us, is not merely about extending the lifespan but expanding the healthspan. Ensuring more years that are healthy, vital, and productive is more crucial. In the Indian context, this requires a unique balance: respect for traditional knowledge systems, alignment with evolving regulatory frameworks, and deep reliance on evidence-based science. We're combining cutting-edge diagnostics—from microbiome and metabolomics to imaging and functional genomics—with culturally compatible interventions and a powerful AI layer. Longevity for us in India means democratising access to health optimisation—life partnerships between human intelligence and machine precision, rooted in science, ethics, and scale. In ancient civilizations including India, people were said to have lived for a much longer span of time. How do you relate that to the work Biopeak is doing and the results it is hoping to achieve? While environmental and societal contexts have changed drastically, ancient systems often emphasised internal balance, rhythm with nature, and preventative health —all are core principles in today's longevity science. At Biopeak, we're not romanticising the past—we're modelling it. Using symbolic and generative AI frameworks, we're integrating timeless health principles with modern biological data to predict individual responses to pharmaceuticals, nutraceuticals, and lifestyle interventions. It's not about replicating ancient lifespans—it's about reclaiming biological potential by harmonising past wisdom with today's precision tools. Do you think longevity as a concept can be realistically spread to all sections of society? Or will it remain only an aspiration of the well-heeled? Longevity must not become a luxury. With AI at the core of Biopeak's platform, we can rapidly model and scale health solutions based on outcomes from higher-touch cases to broader population needs. What starts with the few can be democratised for the many through intelligent design, efficient diagnostics, and continuous learning from diverse cohorts. India has the potential to be a global lab for scalable longevity solutions—not by diluting science but by deploying it with cultural and economic sensitivity. Through our own longitudinal data leveraging interdisciplinary collaboration (Longevity India, an initiative of the Indian Institute of Science), we aim to identify markers of organ system malfunction before pathology sets in so that we can implement a health management program which will extend healthspan and improve the quality of life for the ageing population across all sections of society. At the core of Biopeak's offering, I believe, is a diagnostic system that includes tests like organic acid profiling, microbiome mapping, salivary cortisol rhythms, and whole-exome functional genomics. These are paired with imaging tools such as MRI, CT, and ECHO, as well as tissue-level screenings that examine markers like mineral levels, toxin load, and oxidative stress. Does this make Biopeak a unique company in the world? Yes, Biopeak is unique both in its scientific architecture and its population focus. It combines multiple high-resolution diagnostic modalities—molecular, functional, and structural—into a unified health intelligence platform. Each individual is paired with a biologist and clinician, and guided through a dynamic health roadmap. What further sets it apart is its South Asia-centric design, which considers the genetic, dietary, cultural, and environmental nuances of this region. Supported by research from institutions like IISc and informed by global best practices, Biopeak is not just another health company—it's a systems-level rethink of what human health can be in the 21st century. What's Medicine 4.0? What does it look to solve? What are its basic principles? Medicine 4.0 is the natural evolution of healthcare in the age of AI and high-resolution biology. It's defined by its longitudinal view of health, multisystem diagnostics, real-time feedback loops, and personalised intervention frameworks. It's not about treating symptoms—it's about continuously adapting to the evolving biology of the individual. This approach integrates international technologies, leverages big data with small, precise insights, and focuses on outcomes over time rather than episodic care. In short, it's predictive, participatory, personalised, and preventive. What do you think are the key pillars of the Medicine 4.0 framework as far as BioPeak is concerned? Biopeak leverages data from modern genomics, metabolomics, lipidomics, and metagenomics analytics to provide a molecular view of an individual's unique biology. This integration identifies systemic equilibrium for identifying subtle imbalances and hidden dysfunctions long before symptoms arise. From DXA scans for bone density to functional MRIs and real-time metabolic imaging, Biopeak employs cutting-edge tools that visualise internal systems and structural health markers. Using a hybrid AI approach, combining symbolic AI (for precise, rule-based interpretations) and generative AI (for pattern recognition and predictive modelling), Biopeak can detect complex biological interrelations and generate personalised health insights. What do you think are the limitations of the current health systems worldwide and in India? Globally and in India, health systems remain largely reactive, fragmented, and oriented around acute interventions rather than long-term prevention. There's a heavy focus on managing disease rather than predicting and reversing the conditions that lead to it. What's missing is a systems view—an integration of diagnostics, therapeutics, and lifestyle within a cohesive, continuously updating framework. People are treated as conditions, not as dynamic ecosystems. Long-term biological consequences of current choices are rarely factored into care. The foundation of Medicine 2.0 was built on population averages, with protocols and interventions developed based on data from extensive observational and interventional studies. While this approach helped standardise treatments, it does not account for individual variability. Each person's genetic framework, metabolism, lifestyle, and environment interactions are unique, making the n=1 (individual-first) model essential for true health optimisation. Biopeak is solving for precisely this: unifying the fragmented landscape into an intelligent, longitudinal system centred around the individual.
Entrepreneur
07-06-2025
- Business
- Entrepreneur
Biopeak Raises USD 3.5 Million to Expand AI-Driven Health Clinics
"We're at a unique point where developments in molecular diagnostics, AI, and imaging allow us to understand the human body in unprecedented ways," says Rishi Pardal, Co-founder and CEO of Biopeak Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Biopeak, a wellness and longevity-focused startup headquartered in Bengaluru, has raised USD 3.5 million (approximately INR 29 crore) in seed funding from a group of notable investors. The round saw participation from Accel founding partner Prashanth Prakash, Claypond Capital--the family office of Manipal Group chairman Ranjan Pai and NKSquared, the investment arm of Zerodha co-founder Nikhil Kamath. Founded in 2024 by Rishi Pardal and Shiva Subramanian, Biopeak delivers personalised health services through its own clinics, combining advanced diagnostics, molecular science, and artificial intelligence (AI) to monitor early signs of physiological change. The company launched its first clinic in Bengaluru in March 2025. The funding will be used to expand Biopeak's clinic footprint across key Indian cities and strengthen its AI-based diagnostic and care delivery platform. "We're at a unique point where developments in molecular diagnostics, AI, and imaging allow us to understand the human body in unprecedented ways," said Rishi Pardal, Co-founder and CEO of Biopeak. "Our platform translates these insights into actionable, individualised health plans aimed at extending one's healthspan, not just lifespan." Biopeak's approach includes a suite of diagnostic tools such as microbiome mapping, organic acid profiling, salivary cortisol rhythm analysis, and whole-exome functional genomics. These are integrated with non-invasive imaging technologies including MRI, CT, DXA, and ECHO, along with tissue-level screenings to assess toxin levels, mineral balance, and oxidative stress. Clients typically undergo more than six hours of detailed consultations guided by a dedicated health manager and a multidisciplinary team of specialists. Health plans are updated regularly based on follow-up tests and consultations. Commenting on the investment, Prashanth Prakash said, "As India's population ages, our challenge is to build systems that not only extend life but also improve the quality of those extended years. Geroscience, early interventions, and scalable healthcare models will be central to this shift." Prakash, who also mentors Biopeak, is the Founding Patron of Longevity India, a platform focused on ageing research and interventions tailored for India's demographic needs.
Time of India
06-06-2025
- Business
- Time of India
Trump vs Musk turns ugly; Biopeak‘s fresh funding
Trump vs Musk turns ugly; Biopeak's fresh funding Also in the letter: Trump-Musk spar online as bonhomie turns into brickbats Tell me more: Returning fire: Ceasefire: Also Read: Elon Musk's feud with Trump spurs one of his worst wealth losses ever Longevity startup Biopeak raises $3 million from Ranjan Pai's Claypond Capital, Accel's Prashanth Prakash, others VC fund HealthKois plans $400 million fund Medibuddy eyes $130 million in pre-IPO round: Sponsor ETtech Top 5 & Morning Dispatch! Why it matters: The opportunity: Reach a highly engaged audience of decision-makers. Boost your brand's visibility among the tech-savvy community. Custom sponsorship options to align with your brand's goals. What's next: Infosys to give cash sops to employees taking part in interviews to help hiring Policy details: Employees will receive 700 points, equivalent to Rs 700, for every interview they conduct. The scheme applies retroactively from January 1, covering interviews conducted over the past five months. HR personnel, recruiters, subcontractors, and top leadership are excluded from the scheme. No reward will be given if an interview is cancelled or the candidate fails to show up. Why the move? Who else? OpenAI to appeal New York Times suit demanding not to delete any user chats Story so far: Who's impacted: ChatGPT Free, Plus, Pro, and Team subscribers OpenAI API users without Zero Data Retention agreements, whose data is processed and promptly deleted. 'AI privilege': Also Read: Amazon cuts more jobs, this time in books division More details: Quick lookback: Also Read: Tensions escalated between Elon Musk and Donald Trump as the former sharpened his critique of the Budget Bill. This and more in today's ETtech Top 5.■ Infosys cash sops■ OpenAI appeals order■ Amazon job cutsThe feud between billionaire Elon Musk and US President Donald Trump turned ugly on Thursday, with both sides trading barbs and threats in public an ally, Musk launched a scathing tirade on social media against Trump's 'big, beautiful' Budget Bill, accusing it of inflating the US fiscal deficit by trillions. He didn't stop there; in one post, Musk claimed Trump appeared in the Epstein hit back with personal jibes, calling Musk 'wearing thin' and claiming he had to be 'asked to leave.' He followed through on earlier threats, pulling the plug on government contracts and subsidies linked to Musk's blinked first, signalling he was willing to 'cool off' in his spat with the US blowback was swift. Tesla shares plunged over 14% on Thursday, their steepest fall since March, erasing $153 billion in market value. The shares recouped some losses on Friday, trading in the green during pre-market hours, as tensions between Musk and Trump Pardal, CEO, BiopeakWellness startup Biopeak has raised $3 million in seed funding from Claypond Capital, the family office of Manipal Group chairman Ranjan Pai, along with Accel's Prashanth Prakash, and Zerodha's Rainmatter. The company will use the capital to strengthen its scientific capabilities, build an AI platform, and expand its network of clinics. Biopeak launched its first clinic in Bengaluru and plans to open centres across major metros over the next Janssen, managing partner, HealthKoisDelhi-based venture capital firm HealthKois is planning a $400 million fund to back companies in India's healthcare sector. The fund will focus on startups in AI-led health tech, med tech, biopharma, healthcare delivery, and climate health, managing partner Charles Janssen told us in an exclusive firm Medibuddy is in talks to raise $130 million ahead of its planned IPO, according to people familiar with the Top 5 and Morning Dispatch are must-reads for India's tech and business leaders, including startup founders, investors, policy makers, industry insiders and Reach out to us at spotlightpartner@ to explore sponsorship a bid to boost employee morale, IT major Infosys has introduced a new incentive programme that offers cash rewards to senior staff who participate in lateral hiring company also runs weekend recruitment drives, during which employees may conduct 10-15 interviews in a day, primarily assessing candidates' software skills.A senior Infosys executive said the scheme is aimed at addressing internal discontent after employees received only 5-8% pay hikes for FY24 , and lower-than-expected performance bonuses in the March such policies are still uncommon, some large and mid-sized tech firms, including Honeywell, Accenture, and Sonata Software, offer cash incentives and other perks to encourage staff to join interview panels and support talent Altman, CEO, OpenAIOpenAI has pushed back against a court order in the New York Times' copyright lawsuit, challenging a directive that bars it from deleting any user chats on ChatGPT. The AI firm called the order an overreach that threatens user Times sued OpenAI and Microsoft in 2023, alleging that they had used millions of its articles without permission to train the large language model behind ChatGPT. Last month, a US court directed OpenAI to preserve and segregate all output log data tied to the Times' no impact on ChatGPT Enterprise or ChatGPT Edu CEO Sam Altman warned that the order sets a dangerous precedent. He argued it makes the case for 'AI privilege', where chats with an AI are treated as confidential, akin to conversations with a lawyer, doctor, or giant Amazon has laid off staff in its books division , affecting teams across its Kindle business and book review site than 100 employees have been impacted. Amazon said the move is aimed at improving efficiency and simplifying operations."As part of our ongoing work to make our teams and programs operate more efficiently, and to better align with our business roadmap, we've made the difficult decision to eliminate a small number of roles within the Books organisation," said an Amazon spokespersonA March report by Business Insider revealed Amazon's plans to cut 14,000 management roles globally by early move is in line with CEO Andy Jassy's broader push to reduce bureaucracy and expedite decision-making. He has set a target to increase the proportion of individual contributors relative to managers by at least 15% by the first quarter of 2025.
Time of India
06-06-2025
- Health
- Time of India
Wellness and longevity startup Biopeak raises $3 million from Ranjan Pai's Claypond Capital, Accel's Prashanth Prakash, others
Live Events Wellness startup Biopeak has raised $3 million in seed funding from Claypond Capital—the family office of Manipal Group chairman Ranjan Pai—Accel's Prashanth Prakash, and Zerodha's Bengaluru-based startup has launched its first longevity clinic and plans to expand to other metro cities in the coming year. Biopeak offers a personalised preventive healthcare service, combining diagnostics, AI, and concierge-style care to predict health risks and craft tailored intervention plans.'We offer solutions that are predictive, not reactive,' cofounder and CEO Rishi Pardal told ET. The service includes lab tests, imaging such as MRIs and CT scans, and non-invasive diagnostics to assess organ system health and recommend long-term regimens. 'The funding will go towards building our scientific capabilities, expanding the AI platform, and scaling operations,' Pardal at athletes, health-conscious individuals, and people with unresolved chronic issues like IBS, Biopeak's approach integrates traditional diagnostics with AI insights. The startup has partnered with IISc and Longevity India—a scientific forum backed by Prakash—to tailor interventions for South Asian genetics.'There are breakthroughs in cellular tech and AI-led diagnostics, but they're not widely accessible,' said Prakash. 'Medicine 4.0 is about predictive, proactive care using personalised data. Clinics like Biopeak can deliver this new model of healthcare.'Each Biopeak client undergoes over six hours of multidisciplinary consultation, with specialised modules for gut health, women's health, ageing, skin, and musculoskeletal function.
